AlphaMark Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

AlphaMark Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,310	Closed	-$796K	–	483
2018 Q3	$796K	Sell	9,310 -1,805	-16%	-$181K	0.32%	65
2018 Q2	$1.29M	Sell	11,115 -3,600	-24%	-$359K	0.52%	48
2018 Q1	$1.19M	Sell	14,715 -5,235	-26%	-$403K	0.51%	44
2017 Q4	$1.17M	Sell	19,950 -5,550	-22%	-$278K	0.46%	45
2017 Q3	$1.19M	Sell	25,500 -7,500	-23%	-$301K	0.51%	44
2017 Q2	$1.19M	Hold	33,000	–	–	0.51%	46
2017 Q1	$1.02M	Hold	33,000	–	–	0.47%	49
2016 Q4	$1.11M	Hold	33,000	–	–	0.57%	45
2016 Q3	$878K	Buy	+33,000	New	+$766K	0.44%	57

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

AlphaMark Advisors's ENTA Position: Q4 2018 in Review

AlphaMark Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 9,310 shares — an estimated $796K sold.

AlphaMark Advisors first reported a position in ENTA in Q3 2016 and held it in 9 quarters. The position peaked at $1.29M in Q2 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

AlphaMark Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
AlphaMark Advisors sold 9,310 Enanta Pharmaceuticals shares in Q4 2018, an estimated $796K.
AlphaMark Advisors first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 9 quarters.
AlphaMark Advisors's Enanta Pharmaceuticals position peaked at $1.29M in Q2 2018.
183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on AlphaMark Advisors's 13F filing for Q4 2018, filed 6 Feb 2019.